India Anti-Obesity Drugs Market to Hit USD 190.0 Million to 2025-2033

The latest report by IMARC Group, "India Anti-Obesity Drugs Market Size, Share, Trends and Forecast by Drug Class, Drug Type, Distribution Channel, and Region, 2025-2033," provides a comprehensive analysis of the India anti-obesity drugs market.

The study covers competitor and regional analysis, as well as a detailed breakdown of segments within the industry. The India anti-obesity drugs market size reached USD 80.0 Million in 2024. Looking forward, IMARC Group projects the market to reach USD 190.0 Million by 2033, exhibiting a CAGR of 9.9% during 2025-2033.

Report Attribute and Key Statistics:

Base Year: 2024
Forecast Years: 2025-2033
Historical Years: 2019-2024
Market Size in 2024: USD 80.0 Million
Market Forecast in 2033: USD 190.0 Million
Market Growth Rate (CAGR): 9.9% (2025-2033)

India Anti-Obesity Drugs Market Overview:

The Indian market for anti-obesity medication is expanding at a rapid rate due to rising rates of obesity, increasing health awareness, and improved access to care. Urbanization, lifestyle conditions, and poor diets are the primary causes of the obesity epidemic, and hence more people are demanding prescription and over-the-counter (OTC) anti-obesity medication. Government healthcare schemes and policy changes are also propelling market growth, with preventive care and successful weight management solutions being the prime focus.

Request for Sample Report: https://www.imarcgroup.com/india-anti-obesity-drugs-market/requestsample

India Anti-Obesity Drugs Market Trends and Drivers:

The Indian anti-obesity medications market is witnessing robust growth as physicians and patients increasingly recognize the benefit of medical treatment in weight control. Popularity of prescription medications, including appetite suppressants and fat absorption inhibitors, continues to rise with the approval of newer medications like GLP-1 receptor agonists and new molecules like tirzepatide. Meanwhile, demand for OTC weight loss products with natural extracts and vitamins is on the increase as consumers seek out easy, non-prescription alternatives. The creation of digital health platforms has also improved the accessibility and use of prescription and OTC anti-obesity products.

The key drivers for the India anti-obesity drugs market are increasing obesity incidence due to lifestyle modifications, urbanization, and inappropriate dietary habits. Increased awareness about the health risks of obesity-such as diabetes, cardiovascular disease, and hypertension-has improved the acceptance of medical treatments. Government policies and healthcare reforms are promoting control of obesity, while the increasing penetration of online and retail pharmacies is boosting drug access. Innovation in the pharma industry and approvals of new, efficient drugs are widening treatment options, propelling market growth and improved patient outcomes.

Browse Full Report with TOC & List of Figures: https://www.imarcgroup.com/india-anti-obesity-drugs-market

Key Drivers of the India Anti-Obesity Drugs Market:

• Rising rates of obesity and related health complications
• Increasing health awareness and demand for medical weight management
• Expanding access to healthcare and pharmaceutical products
• Government initiatives and healthcare reforms
• Introduction of new prescription drugs and OTC supplements
• Growth of online and retail pharmacy channels

India Anti-Obesity Drugs Market Segmentation:

IMARC Group provides an analysis of key trends in each segment, with forecasts at the regional level for 2025-2033.

By Drug Class:
• Peripherally Acting Drugs
• Centrally Acting Drugs

By Drug Type:
• Prescription Drugs
• OTC Drugs

By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region:
• North India
• South India
• East India
• West India

Competitive Landscape:

The market research report provides a comprehensive analysis of the competitive landscape, including market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant. Detailed profiles of all major companies are included.

India Anti-Obesity Drugs Market News:

• In July 2024, Eli Lilly and Co. received initial approvals for the import and distribution of its weight-loss drug tirzepatide in India, to be marketed as Zepbound and Mountjaro, ahead of competitors.

• The growing popularity of OTC weight loss supplements and the expansion of digital health platforms are reshaping consumer access and preferences in the market.

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Ask an analyst for your customized sample: https://www.imarcgroup.com/request?type=report&id=31634&flag=C

Contact Us:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No.: (D) +91 120 433 0800
Americas: +1 631 791 1145 | Asia: +91-120-433-0800 | UK: +44-753-714-6104

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.